Phathom Pharmaceuticals Inc — Bilancio Trimestrale (NASDAQ:PHAT) | MetaTrader

Apri il grafico completo

Notizie

Rocket Pharmaceuticals e Argan salgono nel premarket; Two Harbors in lieve calo

Barclays alza il rating di Phathom Pharmaceuticals per le prospettive di fatturato

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

Guggenheim alza il target su Phathom a $25 dopo ricavi record

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Stifel conferma Buy su Phathom, mantiene target $28